Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439594 | 1.00 | CYP1A2 (0.44) | CYP1A2CHRNB4CHRNA3CHRNB1CHRNB2 | |
| SCHEMBL6960581 | 1.00 | CYP1A2 (0.44) | CYP1A2CHRNB4CHRNA3CHRNB1CHRNB2 | |
| SCHEMBL12090069 | 0.93 | CYP1A2 (0.52) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL12985779 | 0.93 | CYP1A2 (0.52) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL12089498 | 0.93 | CYP1A2 (0.52) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL17834046 | 0.86 | — | — | |
| SCHEMBL21859507 | 0.86 | — | — | |
| SCHEMBL17834044 | 0.86 | — | — | |
| SCHEMBL23634572 | 0.83 | CYP1A2 (0.41) | CYP1A2 | |
| SCHEMBL22485709 | 0.83 | CYP1A2 (0.41) | CYP1A2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SPARCBIO LLC | 2023-01-26 | — | — | US | disclosed |
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | NodThera Limited (GB) | 2022-08-25 | — | — | US | disclosed |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | ASCENTAGE PHARMA (SUZHOU) CO., LTD. | 2022-04-26 | — | — | US | disclosed |
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20220056022-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11084812-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-09-06 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
| WO-2005002577-A1 | DUAL NK1/NK3 ANTAGONISTS FOR TREATING SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | COQ8A, SQSTM1, QARS1 | CYP1A2 89/4885CHRNB4 348/4885CHRNA3 168/4885 |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | JAK2, JAK1, JAK3 | CYP1A2 747/4885CHRNB4 4010/4885CHRNA3 3042/4885 |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | CYP1A2 1383/4885CHRNB4 281/4885CHRNA3 184/4885 |
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | CYP1A2 1463/4885CHRNB4 1151/4885CHRNA3 468/4885 |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CYP1A2 747/4885CHRNB4 4010/4885CHRNA3 3042/4885 |
| US-20220267300-A1 | SULFONAMIDE DERIVATIVES AND USES THEREOF | IL1B, IL1A, CASP1 | CYP1A2 715/4885CHRNB4 4883/4885CHRNA3 4876/4885 |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CYP1A2 747/4885CHRNB4 4010/4885CHRNA3 3042/4885 |
| US-20230135560-A1 | GEM-DISUBSTITUTED PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC1R, MC3R, MC2R | CYP1A2 2364/4885CHRNB4 666/4885CHRNA3 369/4885 |
| US-20230250074-A1 | PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS | HCCS, NQO2, SQLE | CYP1A2 81/4885CHRNB4 2720/4885CHRNA3 2730/4885 |
| US-20220056022-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | CYP1A2 4381/4885CHRNB4 3632/4885CHRNA3 4130/4885 |
| US-11084812-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | CYP1A2 4381/4885CHRNB4 3632/4885CHRNA3 4130/4885 |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CYP1A2 747/4885CHRNB4 4010/4885CHRNA3 3042/4885 |
| US-11312724-B2 | Spirocyclic tetrahydroquinazolines | KRAS, NRAS, HRAS | CYP1A2 1287/4885CHRNB4 4848/4885CHRNA3 4659/4885 |
| US-20230026856-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | CYP1A2 3378/4885CHRNB4 4547/4885CHRNA3 4580/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | CYP1A2 747/4885CHRNB4 4010/4885CHRNA3 3042/4885 |
| US-20230023009-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | CYP1A2 3378/4885CHRNB4 4547/4885CHRNA3 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.